switching from semaglutide to tirzepatide dosing vs. Semaglutide: What You Should Know Switching from tirzepatide to semaglutide

For each major obesity-related complication, annual incidence rates were estimated for the two comparator populations: patients receiving semaglutide 2.4 mg, achieving an average body weight reduction of 15%, and untreated patients, for which weight stability was assumed

Healthcare workers, teachers, or those in customer-facing roles might strategically time injections to minimize potential interference with professional obligations

Active ingredient and concentration: Semaglutide

Olivia Svolgaard 1

Semaglutide (2.4 mg/week), approved in 2021, delivers improved weight loss compared to the earlier treatments and represents considerable progress in obesity pharmacotherapy (13)